Abstract
(Molecular Therapy 24, 1267–1277; July 2016) In the originally published version of this article, Figure 1d and the associated legend should have appeared as below: (d) 10% native TBM PAGE of A9g-3WJ-anti-miR21 nanoparticle (upper panel) and the scramble control aptamer (MG)-3WJ-anti-miR21 nanoparticle (lower panel). The upper panel and the lower panel contain the same RNA materials ran on the same gel on each side of the electrophoresis apparatus, the only difference is the A9g-PSMA RNA aptamer was replaced with the scramble sequence. Lane 3 in the upper panel is spliced from the same miRNA21 LNA used in both gels for the tested PSMA aptamer and scramble control (see dotted line in lane 3). Although the scientific conclusion does not change, the authors apologize for this error and any confusion this may have caused.(Figure presented).
| Original language | English |
|---|---|
| Pages (from-to) | 6554 |
| Number of pages | 1 |
| Journal | Molecular Therapy |
| Volume | 33 |
| Issue number | 12 |
| DOIs |
|
| State | Published - Dec 3 2025 |
Fingerprint
Dive into the research topics of 'Erratum to: Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology (Molecular Therapy, (2016), 24, 7, (1267-1277), (S1525001616303598), 10.1038/mt.2016.85)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver